Literature DB >> 2393293

Penetration of ampicillin and sulbactam in the lower airways during respiratory infections.

Y J Valcke1, M T Rosseel, R A Pauwels, M G Bogaert, M E Van der Straeten.   

Abstract

We studied the penetration of ampicillin-sulbactam in the alveolar lining fluid (ALF) of eight patients after intravenous administration of 2,000 mg of ampicillin and 1,000 mg of sulbactam three times daily over 30 min. Bronchoalveolar lavage was performed on day 3, 30 min after the end of the morning drug administration. The mean penetration ratios (i.e., the ratios of the concentrations in ALF versus those in serum) were 53% (standard error, 12%) and 61% (standard error 31%) for ampicillin and sulbactam, respectively. The concentration ratio of ampicillin versus sulbactam in serum was not significantly different from that in ALF. From a pharmacokinetic point of view, ampicillin-sulbactam is a good choice for treatment of infectious exacerbation of chronic obstructive pulmonary disease and community-acquired bacterial pneumonia, since the concentrations of both drugs in ALF exceed the MICs for the respiratory pathogens responsible.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2393293      PMCID: PMC171737          DOI: 10.1128/AAC.34.6.958

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Penetration of antimicrobial agents into bronchial secretions.

Authors:  G A Wong; T H Pierce; E Goldstein; P D Hoeprich
Journal:  Am J Med       Date:  1975-08       Impact factor: 4.965

2.  TREATMENT OF CHRONIC BRONCHITIS WITH AMPICILLIN: SOME PHARMACOLOGICAL OBSERVATION.

Authors:  J R MAY; D M DELVES
Journal:  Lancet       Date:  1965-05-01       Impact factor: 79.321

3.  Pharmacokinetic study of beta-lactam antibiotics in bronchial secretions.

Authors:  E Bergogne-Berezin; C Morel; Y Benard; G Berthelot; H Kafe
Journal:  Scand J Infect Dis Suppl       Date:  1978

4.  Ampicillin levels in sputum, serum, and saliva.

Authors:  S M Stewart; M Fisher; J E Young; W Lutz
Journal:  Thorax       Date:  1970-05       Impact factor: 9.139

Review 5.  Bronchial tree penetration of antibiotics.

Authors:  B R Smith; J L LeFrock
Journal:  Chest       Date:  1983-06       Impact factor: 9.410

6.  Pulmonary disposition of tobramycin.

Authors:  A C Braude; A Hornstein; M Klein; S Vas; A S Rebuck
Journal:  Am Rev Respir Dis       Date:  1983-05

Review 7.  Penetration of antibiotics into respiratory secretions.

Authors:  J E Pennington
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

8.  Pulmonary disposition of cortisol.

Authors:  A C Braude; A S Rebuck
Journal:  Ann Intern Med       Date:  1982-07       Impact factor: 25.391

9.  Branhamella catarrhalis: antibiotic sensitivities and beta-lactamases.

Authors:  E E Stobberingh; B I Davies; C P van Boven
Journal:  J Antimicrob Chemother       Date:  1984-01       Impact factor: 5.790

10.  Pulmonary disposition of moxalactam.

Authors:  A C Braude; R D Cohen; J L Penner; M A Preston; A S Rebuck
Journal:  Chest       Date:  1984-12       Impact factor: 9.410

View more
  10 in total

1.  Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations.

Authors:  Brian J Werth; Laura M Shireman
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

2.  Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

3.  Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.

Authors:  J Majcher-Peszynska; M Loebermann; S Klammt; S Frimmel; R G Mundkowski; T Welte; E C Reisinger; B Drewelow
Journal:  Infection       Date:  2013-08-01       Impact factor: 3.553

4.  In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.

Authors:  M Wolff; M L Joly-Guillou; R Farinotti; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Robin D Isaacs; John P O'Donnell; Emily Stone
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

6.  Concentrations of sulbactam/ampicillin in serum and lung tissue.

Authors:  U Frank; E Schmidt-Eisenlohr; A Joos-Württemberger; J Hasse; F Daschner
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

7.  Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study.

Authors:  A Acquarolo; T Urli; G Perone; C Giannotti; A Candiani; N Latronico
Journal:  Intensive Care Med       Date:  2005-03-08       Impact factor: 17.440

Review 8.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

9.  In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.

Authors:  Paul G Higgins; Hilmar Wisplinghoff; Danuta Stefanik; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients.

Authors:  C Muller-Serieys; C Bancal; M C Dombret; P Soler; G Murciano; M Aubier; E Bergogne-Berezin
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.